RxSight, Inc. (NASDAQ:RXST) Insider Sells $154,318.00 in Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $49.78, for a total transaction of $154,318.00. Following the completion of the transaction, the insider now owns 42,246 shares in the company, valued at $2,103,005.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,529.45.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.19, for a total transaction of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total value of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $48.26, for a total value of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.01, for a total value of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.02, for a total transaction of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $53.19, for a total transaction of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The stock was sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Trading Up 0.9 %

Shares of NASDAQ:RXST traded up $0.44 on Friday, hitting $50.47. The company had a trading volume of 363,912 shares, compared to its average volume of 473,295. RxSight, Inc. has a 1-year low of $20.66 and a 1-year high of $66.54. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of -49.48 and a beta of 1.20. The stock has a 50 day moving average price of $52.13 and a 200 day moving average price of $53.82.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.06. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. The business had revenue of $34.89 million for the quarter, compared to the consensus estimate of $32.33 million. During the same period in the prior year, the company posted ($0.40) earnings per share. RxSight’s revenue was up 67.6% compared to the same quarter last year. Sell-side analysts anticipate that RxSight, Inc. will post -0.81 earnings per share for the current fiscal year.

Hedge Funds Weigh In On RxSight

Institutional investors and hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP acquired a new position in shares of RxSight in the first quarter valued at about $1,929,000. Principal Financial Group Inc. grew its stake in shares of RxSight by 298.5% in the first quarter. Principal Financial Group Inc. now owns 34,928 shares of the company’s stock valued at $1,802,000 after acquiring an additional 26,164 shares in the last quarter. Baillie Gifford & Co. acquired a new position in shares of RxSight in the first quarter valued at about $3,429,000. M&G Plc acquired a new position in shares of RxSight in the first quarter valued at about $7,354,000. Finally, Inspire Investing LLC acquired a new position in shares of RxSight in the first quarter valued at about $917,000. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on RXST. BTIG Research upped their price objective on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Stifel Nicolaus dropped their price target on RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Oppenheimer reduced their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research report on Tuesday, August 6th. Wells Fargo & Company decreased their price objective on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price objective on shares of RxSight in a report on Friday, September 13th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, RxSight presently has an average rating of “Buy” and an average target price of $60.14.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.